📰 Key Statistics News
Page 44 - Key Statistics News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Key Statistics. Real-time updates on events, politics, business and more.
July 8, 2022
(BPT) - Sponsored by GSKDespite ovarian cancer striking all races at similar rates, Black Americans are 20% more likely to receive a late-stage diagnosis1 and 30% more likely to die from the disease than white Americans.2 The reasons are complex &mdash...
July 2, 2022
–Phase 2 trial showed chemotherapy-free TUKYSA combination resulted in clinically meaningful and durable tumor responses––Results presented in late-breaking oral session at the ESMO World Congress on Gastrointestinal Cancer–BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced full results from...
July 2, 2022
-Phase 2 trial showed chemotherapy-free TUKYSA combination resulted in clinically meaningful and durable tumor responses- -Results presented in late-breaking oral session at the ESMO World Congress
June 7, 2022
The production of plastic has skyrocketed in recent decades, using 6% of world oil, emitting GHGs, and inflicting environmental harm to natural habitats and ecosystems. Plastic waste is a big concern as it accounts for 12% of worldwide waste and poses health risks to coastal areas. This article will
May 31, 2022
Stagflation, a mix of weak growth and inflation, may come. Some hotel companies may be more resilient than others if stagflation appears.
May 28, 2022
U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma - read this article along with other careers information, tips and advice on BioSpace
May 28, 2022
U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 25, 2022
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and...
May 25, 2022
TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based
May 25, 2022
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and...